Renal function and acute heart failure outcome.

Renal function and acute heart failure outcome. Med Clin (Barc). 2018 Jun 05;: Authors: Llauger L, Jacob J, Miró Ò Abstract The interaction between acute heart failure (AHF) and renal dysfunction is complex. Several studies have evaluated the prognostic value of this syndrome. The aim of this systematic review, which includes non-selected samples, was to investigate the impact of different renal function variables on the AHF prognosis. The categories included in the studies reviewed included: creatinine, blood urea nitrogen (BUN), the BUN/creatinine quotient, chronic kidney disease, the formula to estimate the glomerular filtration rate, criteria of acute renal injury and new biomarkers of renal damage such as neutrophil gelatinase-associated lipocalin (NGAL and cystatin c). The basal alterations of the renal function, as well as the acute alterations, transient or not, are related to a worse prognosis in AHF, it is therefore necessary to always have baseline, acute and evolutive renal function parameters. PMID: 29884452 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Related Links:

Conclusions: In this retrospective analysis of GIAD at a single institution, patients with NISGIAD compared with ISGIAD had a 4 times odds of rebleeding within 1 year after capsule endoscopy. This is a novel study, as the distribution of GIAD has not been previously described as being a risk factor for rebleeding.
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research
ConclusionIt is clear that natural phenolic compounds have some potential inhibitory effect on NADPH oxidase activity. In comparison to other phenolic plant compounds, the structural varability of the flavonoids should off different impacts on oxidative stress in hypertension including inhibition of nadph oxisdase and direct scavenging of free radicals.
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 1 August 2018Source: American Heart JournalAuthor(s): Sripal Bangalore, David J. Maron, Jerome L. Fleg, Sean M. O’Brien, Charles A. Herzog, Gregg W. Stone, Daniel B. Mark, John A. Spertus, Karen P. Alexander, Mandeep S. Sidhu, Glenn M. Chertow, William E. Boden, Judith S. Hochman, on behalf of the ISCHEMIA-CKD Research GroupAbstractBackgroundPatients with chronic kidney disease (CKD) and stable ischemic heart disease (SIHD) are at markedly increased risk of cardiovascular events. Prior trials comparing a strategy of optimal medical therapy (OMT) with or without revascularization hav...
Source: American Heart Journal - Category: Cardiology Source Type: research
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation. PMID: 30025513 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Publication date: August 2018Source: American Journal of Kidney Diseases, Volume 72, Issue 2Author(s): Andrew A. HouseHeart failure and chronic kidney disease have increasing incidence and prevalence owing in part to the aging population and increasing rates of hypertension, diabetes, and other cardiovascular and kidney disease risk factors. The presence of one condition also has a strong influence on the other, leading to greater risks for hospitalization, morbidity, and death, as well as very high health care costs. Despite the frequent coexistence of heart failure and chronic kidney disease, many of the pivotal randomiz...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
AbstractPatiromer (Veltassa®) for oral suspension is a non-absorbed, sodium-free potassium binding polymer that exchanges calcium for potassium in the gastrointestinal (GI) tract, thereby increasing faecal potassium excretion and reducing serum potassium levels. Patiromer was approved in the USA in 2015 and is now approved in several other countries, including those of the EU, for the treatment of hyperkalaemia in adults. In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart fai...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
One common cluster of chronic conditions — chronic kidney disease, diabetes mellitus and heart failure — places a significant burden on the Australian healthcare system. In combination, these conditions complicate treatment, increase rates of hospitalisation and carry a poorer prognosis for survival. Current health services are organis ed around single conditions, making coordination of care more difficult and adding complexity to patients’ lives.
Source: Collegian - Category: Nursing Authors: Source Type: research
ConclusionIn patients admitted for AHF without renal failure or CKD, WRF with HC is associated with a better prognosis, similar to that of patients without WRF, and should therefore be reclassified as ‘pseudo-WRF’.ResumoIntroduçãoAlterações na função renal com aumento da creatinina têm sido associadas a maior mortalidade em doentes com insuficiência cardíaca aguda (ICA). Já a hemoconcentração na ICA tem-se associado a redução da mortalidade, é também uma causa de elevação da creatinina. Av...
Source: Revista Portuguesa de Cardiologia - Category: Cardiology Source Type: research
Abstract BACKGROUND: Although chronic kidney disease (CKD) is associated with various outcomes, the burden of each condition for hospital admission is unknown. AIM: To quantify the association between CKD and cause-specific hospitalisation. DESIGN AND SETTING: A matched cohort study in primary care using Clinical Practice Research Datalink linked to Hospital Episode Statistics in England. METHOD: Patients with CKD (estimated glomerular filtration rate
Source: The British Journal of General Practice - Category: Primary Care Authors: Tags: Br J Gen Pract Source Type: research
Authors: Ono Y, Takamatsu H, Inoue M, Mabuchi Y, Ueda T, Suzuki T, Kurabayashi M Abstract The effectiveness of long-term administration of tolvaptan in heart failure (HF) patients with chronic kidney disease (CKD) has not been fully studied. Hence, in this study, we investigated the effects of chronic administration of tolvaptan on patients with HF and CKD. We consecutively enrolled 31 patients with acute HF syndrome (AHFS) who were administrated tolvaptan as a long-term medication (TLV group). All patients had a history of prior HF admission and CKD. We also consecutively enrolled 27 patients with AHFS, a prior hi...
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research
More News: Cardiology | Chronic Kidney Disease | General Medicine | Heart | Heart Failure | Study | Urology & Nephrology